HB 408 requires most health insurance policies and health coverage plans issued or renewed in Louisiana to cover diagnosis and treatment for pediatric acute-onset neuropsychiatric syndrome (PANS), pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), and related types of autoimmune encephalitis (AE). The bill specifically includes coverage for intravenous immunoglobulin therapy and allows insurers to apply ordinary plan cost-sharing such as deductibles, coinsurance, and copayments. It also permits insurers to consider treatment guidance from medical professional consortia, but does not require strict adherence to those recommendations, and it limits IVIG coverage to up to three monthly courses unless additional treatment is found medically necessary through clinical review.
The bill adds a new statute, R.S. 22:1028.6, to Louisiana insurance law and defines the covered conditions and the term "health coverage plan." It excludes certain coverage arrangements, including the Office of Group Benefits, excepted benefits, limited-benefit plans, and short-term policies under 12 months. The law applies to new policies issued on or after January 1, 2026, and requires existing policies to conform by renewal, but no later than January 1, 2027. The act is also designated as the "The Gillian Guiffreda Act."
The stated legislative findings emphasize that these conditions can cause serious neurological and behavioral symptoms, are sometimes misdiagnosed, and may require early treatment to avoid long-term harm. The findings also cite therapies such as antibiotics, IVIG, antidepressants, cognitive behavioral therapy, and plasma exchange as potentially effective treatments. Overall, the bill’s impact is to mandate insurance coverage for a specialized set of pediatric neuroimmune disorders and to expand access to related treatments for affected families.
The general sentiment around the bill appears strongly supportive and largely noncontroversial in the recorded votes, with unanimous passage in both chambers and unanimous concurrence in the House on Senate amendments. No committee transcript was provided, so there is no recorded floor or committee debate to indicate organized opposition. The absence of nay votes suggests broad bipartisan agreement, likely driven by the bill’s focus on coverage for children with serious medical conditions.
Notable points of potential contention in the bill itself include the scope of required coverage, the use of IVIG therapy, and the extent to which insurers may rely on outside treatment guidelines or clinical review to limit treatment. The bill also raises the usual insurance-policy issues of mandated benefits, cost-sharing, and applicability to self-insured or excluded plans. However, based on the voting record, these issues did not produce visible opposition during final consideration.
HB 408 creates a new mandatory health insurance benefit in Louisiana by adding R.S. 22:1028.6 to require coverage for PANS, PANDAS, and related autoimmune encephalitis treatments in most health coverage plans. It affects insurers, health plans, and covered policyholders by expanding required benefits, while preserving standard deductibles and copayments and excluding certain plan types such as Office of Group Benefits and short-term policies. The law takes effect for new policies on or after January 1, 2026, with existing plans required to conform by renewal no later than January 1, 2027.
The bill appears to have enjoyed very strong support. It passed the House 95-0, the Senate 39-0, and the House again 95-0 on concurrence, indicating unanimous or near-unanimous approval at each stage. With no committee transcripts available, there is no documented debate, but the vote totals suggest broad bipartisan acceptance of the measure as a health coverage mandate for children with serious neuroimmune conditions.
The main policy questions raised by the text concern whether insurers should be required to cover specialized and potentially costly treatments such as intravenous immunoglobulin, how much deference should be given to outside medical guidelines, and whether treatment should be capped absent clinical review. Another possible point of contention is the bill’s reach across different insurance products, since it excludes some plans while applying broadly to most others. Despite these issues, the recorded votes show no visible opposition, so any disagreement was either resolved before final passage or not significant enough to affect the outcome.